Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 10,628 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Cystic Fibrosis
Interventions: AquADEKs-2, control multivitamin; Drug · Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Tucson, Arizona • Aurora, Colorado • Orlando, Florida + 12 more

Conditions: Cerebrospinal Fluid Leak
Interventions: FS VH S/D 500 s-apr, DuraSeal Dural Sealant; Drug · Device
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more

Conditions: Candidemia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Birmingham, Alabama • Augusta, Georgia • Detroit, Michigan + 3 more

Conditions: Acromegaly
Interventions: Paltusotine; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: gene mapping; Genetic
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 0 Years to 120 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 32
States / cities: Rancho Mirage, California • Fort Collins, Colorado • Boca Raton, Florida + 22 more

Conditions: Cushing's Syndrome
Interventions: CORT125134; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Laguna Hills, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more

Conditions: Hemorrhagic Shock, Trauma Injury
Interventions: Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT); Biological · Drug
Lead sponsor: Philip Spinella; Other
Eligibility: Up to 17 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions: Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 36
States / cities: Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more

Conditions: Colorectal Cancer
Interventions: leucovorin calcium, tegafur-uracil; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 75 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 49
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more

Conditions: Urea Cycle Disorders
Interventions: HPN-100, Buphenyl (NaPBA); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Long Beach, California • Los Angeles, California • Stanford, California + 18 more

Conditions: Ischemic Stroke
Interventions: Not listed
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: Not listed
Enrollment: 2,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 47
States / cities: Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 40 more

Conditions: Cancer
Interventions: Vopratelimab, Ipilimumab; Drug
Lead sponsor: Jounce Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Beverly Hills, California • Los Angeles, California • Newark, Delaware + 15 more

Conditions: Maxillary Expansion
Interventions: 3D-Printed Hyrax Expander, Conventional Laboratory Fabricated Hyrax Expander; Device
Lead sponsor: Ildeu Andrade Jr.; Other
Eligibility: 8 Years to 13 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Charleston, South Carolina

Conditions: Acute Pain, Headache, Musculoskeletal Pain
Interventions: Usual Care/Guideline, Opioid Justification, Provider Comparison; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 22,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Therapeutic Drug Monitoring (TDM); Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 86
States / cities: Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more

Conditions: Chronic Kidney Disease Requiring Hemodialysis
Interventions: Technology Assisted Stepped Collaborative Care, Usual Care Arm; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Pittsburgh, Pennsylvania

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions: Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 31 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more

Conditions: Prevention
Interventions: Tenofovir 1% vaginal gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Aortic Coarctation
Interventions: Treatment of Aortic Wall Injury; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Down Syndrome
Interventions: Placebo, RO5186582; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Phoenix, Arizona • Decatur, Georgia • Chicago, Illinois + 5 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 48
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 28 more

Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions: MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 22 Months to 60 Months
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 21
States / cities: Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more

Search by objective public record fields.

Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery

Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer

Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

Trevo® Retriever Registry Post Market Surveillance

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

3D-Printed Versus Laboratory-Fabricated Hyrax Expanders

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB